Business Wire

LBC Tank Terminals Holding Netherlands B.V. Announces Q4 FY17 Financial Results Conference Call

Del

LBC Tank Terminals announced today it will hold a conference call to discuss its financial results for Q4 FY17 ended 30 June 2017.

The results will be published today, Friday, 27th October 2017, followed by a conference call for all investors on Monday, 6th November 2017 at 16:00 (Central European Time) / 10:00 (Eastern Standard Time).

Call details and copies of the financial statements will be made available on the Intralinks website.

Investors of LBC Tank Terminals Holding Netherlands B.V. Senior Notes, due 2023, can request access to Intralinks by contacting investors@lbctt.com.

LBC Tank Terminals

LBC Tank Terminals is a top-tier global independent operator of bulk liquid storage facilities for petrochemicals, petroleum products and base oil products. LBC owns and operates a global network of terminals at key locations in the United States, Europe and China, while offering loading / unloading services for all modes of transportation. Underlying the entire ethos of the company is our focus on corporate and social governance in which we strive to have a positive effect upon society and ensure that there is no such thing as a dangerous product, at least not when under our care. More information is available at www.lbctt.com

Contact information

LBC Belgium Holding NV
Steven Pauwels, 0032 15 28 73 10
s-pauwels@lbctt.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar18.6.2018 02:53Pressemelding

Celltrion (KRX:068270) has made a resubmission to the FDA (U.S. Food and Drug Administration) to obtain its marketing approval for CT-P6, a proposed mAb biosimilar to Herceptin® (trastuzumab). Celltrion submitted its abbreviated Biologics License Applications (aBLAs) for CT-P10 and CT-P6 to the FDA in April and May of last year, respectively. However, it received CRLs (complete response letters) from the FDA related to the warning letter issued by the FDA in January 2018, related to the manufacturing facility in Incheon, South Korea. Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be usually finalized within six months from the resubmission, so Celltrion expects the approval for the U.S. market of the two proposed biosimilars within this calendar year. FDA has notified Celltrion of its re-inspection schedule regarding regular audit results, and

CES Asia: Innovation at the Speed of 5G15.6.2018 14:59Pressemelding

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 10:00Pressemelding

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

AGP Group Announces the Acquisition of Soliver NV in Belgium, Representing a Key Step towards Becoming the Premier Global Leader in Designing and Manufacturing High-Tech Automotive Glazing15.6.2018 09:00Pressemelding

AGP, a high-tech specialty glass designer and manufacturer, has announced today the acquisition of Soliver NV, a European automotive glazing manufacturer with over 65 years of solid product and brand reputation. Soliver offers high-quality tempered and laminated glazing for high-end automobiles, as well as windshield solutions for trucks. AGP’s glazing heritage started in Berlin, with the Mannheim family´s first glass company. After 100 years and a clear vision to become a leader in specialty glass, AGP’s core eGlass technologies have responded to the rising demand in electrification, connectivity, shared mobility and autonomous driving, acting as an enabler of future mobility trends. The integration of Soliver into the AGP Group will strengthen the AGP eGlass value proposition and will be a game changer in a fast-evolving industry. “We are very excited to build upon Soliver’s great experience and track-record to take high-tech glazing to the next level, enabling our customer’s product

Rivoli Group announces completion of its new international corporate strategy15.6.2018 07:00Pressemelding

Rivoli Group AG completes its comprehensive operational restructuring process and acts with a new presence in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180615005085/en/ Rivoli Group Announces Completion of Its New International Corporate Strategy (Photo: Business Wire) The Swiss based Rivoli Group AG has now completed the comprehensive restructuring process as part of the international realignment of its corporate strategy. After an intensive evaluation of the situation, the available resources and existing market potential, the Chairman of the Board of Directors Mr. Mourad Malloul, the management team and an international advisory committee coordinated the strategy together. "This is the beginning of a crucial new chapter for the Rivoli Group," the President and CEO of Rivoli Group AG said. The measure aims to strengthen the competitive advantages within the company group, to adjust their service offerings